Tools for Monitoring and Managing Inappetence
These downloadable tools are provided to help you, your staff and pet owners recognize inappetence and how you can use ENTYCE® (capromorelin oral solution) as a therapeutic solution for stimulating appetite in your canine patients.
ENTYCE is a once-daily oral solution. The drug concentration is 30 mg/mL with the recommended dose of 3 mg/kg (1.4 mg/lb). See this ENTYCE Dosing Chart for appropriate dosing based on the weight of your canine patient.
Inappetence Overview Sheet
Early recognition of changes in a canine’s appetite is important to allow the veterinarian to diagnose and treat the underlying cause. Check out this resource to review the signs, multitude of causes and impact of inappetence.
Pet Owner Inappetence Questionnaire
This quick, 5-question sheet is designed to help pet owners identify and monitor any changes in eating behavior that may warrant a discussion with you.
IMPORTANT SAFETY INFORMATION: ENTYCE® (capromorelin oral solution) is for use in dogs only. Do not use in breeding, pregnant or lactating dogs. Use with caution in dogs with hepatic dysfunction or renal insufficiency. Adverse reactions in dogs may include diarrhea, vomiting, polydipsia, and hypersalivation. Should not be used in dogs that have a hypersensitivity to capromorelin. Please see the full Prescribing Information for more detail.
Other therapeutics from Aratana
NOCITA® (bupivacaine liposome injectable suspension) is the only long-acting local anesthetic that controls cranial cruciate ligament (CCL) post-op pain with one dose for up to 72 hours.
You can be sure that the local relief will help keep your patient is comfortable even after going home.
IMPORTANT SAFETY INFORMATION: NOCITA® (bupivacaine liposome injectable suspension) is for use in dogs only. Do not use in dogs younger than 5 months of age, dogs used for breeding, or in pregnant or lactating dogs. Do not administer by intravenous or intra-arterial injection. Adverse reactions in dogs may include discharge from incision, incisional inflammation and vomiting. Avoid concurrent use with bupivacaine HCl, lidocaine or other amide local anesthetics. Please see the full Prescribing Information for more detail.